Viveve Medical, Inc. announced the launch of a company-wide rebranding initiative that will include content and new graphic elements related to the treatment of SUI in women. The rebranding is being completed in advance of the planned reporting of topline results from the company's pivotal U.S. PURSUIT clinical trial in early 2023. The company rebranding effort premiers a new corporate website that includes content addressing the prevalence of SUI in women and the current unmet need for a noninvasive treatment option.

Stylish new design elements include vibrant color palettes, updated graphic elements and new layout for easy access to information for clinicians, investors, patients, and other audiences. The new brand designs will be carried through all customer and public-facing communications from the company including presentations, educational materials in both print and digital media, and the company's social media channels.